Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/27/2025

Management of Fatty Liver Disease with Normal LFTs

Initial Risk Stratification

  • The American Association for the Study of Liver Diseases recommends calculating FIB-4 score immediately to identify patients at risk for advanced fibrosis, as normal LFTs do not exclude significant liver disease 3, 2
  • Patients with FIB-4 <1.3 have very low risk of liver-related events (2.6 per 1000 patient-years) and should be managed in primary care with focus on lifestyle and cardiovascular risk 3, 2
  • For FIB-4 scores in the indeterminate range, obtain second-tier testing with ELF score or transient elastography (LSM >8 kPa or ELF >9.5 warrants hepatology referral) 3, 2
  • Reassess fibrosis risk every 3 years in low-risk patients, or every 1-3 years in those with diabetes or ongoing weight gain 5, 3

Lifestyle Modification Protocol

  • The European Association for the Study of the Liver recommends targeting 7-10% total body weight reduction through caloric restriction of 500-1000 kcal/day 1, 6
  • Weight loss >5% improves steatosis and inflammation; >10% achieves near-universal NASH resolution and fibrosis regression 3
  • Adopt a Mediterranean diet pattern as the primary dietary approach, which reduces liver fat even without weight loss 1, 4
  • Engage in 150-300 minutes per week of moderate-intensity aerobic exercise, or 75-150 minutes of vigorous-intensity exercise, spread over minimum 3 days per week 1, 4, 6

Cardiovascular Risk Management

  • Screen annually for type 2 diabetes using HbA1c (≥48 mmol/mol or 6.5% is diagnostic), as NAFLD patients have 3-fold increased diabetes risk 1
  • Assess lipid profile and blood pressure at baseline, as NAFLD independently increases hypertension risk 3-fold 1
  • Treat dyslipidemia with statins according to cardiovascular risk, as statins are safe in NAFLD (including compensated cirrhosis) and reduce HCC risk by 37% 7, 6

Alcohol and Tobacco Assessment

  • Obtain quantitative alcohol history at baseline and reassess regularly, as alcohol has additive/synergistic effects with metabolic risk factors in fatty liver progression 1, 5
  • Minimize alcohol consumption beyond national limits, as it provides additional calories that worsen metabolic risk 1
  • Document smoking history and refer current smokers to cessation services, as smoking markedly increases cardiovascular and all-cause mortality 1

Medication Review

  • Review all medications and consider discontinuing agents that worsen steatosis, including corticosteroids, amiodarone, methotrexate, tamoxifen, sodium valproate, and certain antiretrovirals 5, 4

Monitoring Schedule

  • Repeat fibrosis assessment every 3 years in patients without risk factors for progression who achieve weight loss goals 5, 3
  • Establish triggers for re-referral to hepatology if FIB-4 increases to indeterminate/high range or if new metabolic comorbidities develop 7

Common Pitfalls

  • Do not assume normal LFTs exclude significant fibrosis—95% of patients with fatty liver may have normal transaminases, yet some harbor advanced disease 3
  • Avoid focusing solely on liver outcomes; cardiovascular disease and non-hepatic malignancy are the primary causes of death in low-risk NAFLD patients 3, 2
  • Do not withhold statins due to liver concerns—hepatotoxicity is extremely rare and cardiovascular benefits significantly outweigh risks 7

REFERENCES

5

Management of Grade 3 Fatty Liver Disease [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

6

Fatty Liver Disease Management Recommendations [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025